970*90
768
468
mobile

Novartis AG to acquire US-based Endocyte for $2.1 billion

Franchise India Bureau
Franchise India Bureau Oct 19 2018 - 1 min read
Novartis AG to acquire US-based Endocyte for $2.1 billion
The US-based firm said that the deal will help develop a broader role for radioligand therapies in cancer treatment.

Novartis AG will acquire Endocyte Inc, a US-based cancer drugmaker, in an all-cash deal for $ 24 per share, or a total equity value of about $ 2.1 billion. This acquisition will expand the radiopharmaceuticals business of the Swiss drugmaker.

The US-based firm said that the deal will help develop a broader role for radioligand therapies in cancer treatment.

With this acquisition, Novartis will investigate the potential development of a drug candidate for use in earlier lines of prostate cancer therapy.

As part of the transaction, Endocyte will be merged with a newly-formed Novartis subsidiary. The deal is likely to be completed in the first half of 2019. Until then, Endocyte will continue to operate as a separate and independent firm.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online